DNTH (Dianthus Therapeutics, Inc.) Stock Market Reviews

crown

search

Read and share opinions on DNTH (Dianthus Therapeutics, Inc.) stock. Join MyTopStock.com to discover reviews, insights, and discussions from investors about this company's performance in the stock mar

DNTH

Dianthus Therapeutics, Inc.

clarify Biotechnology

bookmark Healthcare

public United States

Sell Neutral Buy

Latest News

Assessing Dianthus Therapeutics (DNTH) Valuation Following Strong Revenue Growth and Recent Share Price Momentum
Nov 7, 2025
Dianthus Therapeutics, Inc. (DNTH) Reports Q3 Loss, Lags Revenue Estimates
Nov 5, 2025
Dianthus Therapeutics to Participate in Four Investor Conferences During November
Nov 4, 2025
Dianthus Therapeutics, Inc. (DNTH) Expected to Beat Earnings Estimates: Should You Buy?
Oct 30, 2025
Evaluating Dianthus Therapeutics (DNTH) Valuation After New DNTH212 Licensing Deal and Pipeline Expansion
Oct 17, 2025
Dianthus Enters License Agreement for Autoimmune Drug; Shares Rise
Oct 16, 2025
Dianthus Therapeutics Announces Exclusive License Agreement with Leads Biolabs for DNTH212, a First and Potentially Best-In-Class, Phase 1 Ready Bifunctional BDCA2 & BAFF/APRIL Inhibitor for Severe Autoimmune Diseases
Oct 16, 2025
Dianthus Therapeutics Highlights Claseprubart Data Presentations Planned for 2025 AANEM Annual Meeting
Oct 2, 2025
Clear Street Initiates Buy on Dianthus Therapeutics, Inc. (DNTH) With $100 Price Target
Sep 30, 2025
Dianthus Therapeutics, Inc. Announces Closing of its Upsized $288 Million Underwritten Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
Sep 11, 2025
Dianthus Therapeutics, Inc. Announces Pricing of Upsized $251 Million Underwritten Public Offering
Sep 10, 2025
Dianthus Therapeutics (DNTH) Hits New High as Drug Trial Sparks Optimism for Blockbuster Potential
Sep 9, 2025

Reviews